[Abstract] [Full Text PDF] (in Japanese / 2207KB) [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 90(10): 1758-1764, 1989


Original article

EXTRACORPOREAL ADRIAMYCIN-REMOVAL FOLLOWING HEPATIC ARTERY INFUSION : USE OF DIRECT HEMOPERFUSION COMBINED WITH VENO-VENOUS BYPASS

The 1st Department of Surgery, Kobe University School of Medicine, Kobe, Japan

Yonson KU, Masaki Saitoh, Hiroyasu Nishiyama, Sumio Fujiwara, Takeshi Iwasaki, Harumasa Ohyanagi, Yoichi Saitoh

Systemic toxicity of adriamycin (ADR) has limited its high dosage application in hepatic artery infusion. We developed a new extracorporeal device combining direct hemoperfusion (DHP) and veno-venous bypass to eliminate ADR following hepatic artery infusion.
Mongrel dogs were devided into three group, I : controls without DHP (n=3), II : DHP under single venous bypass from IVC to left external jugular vein (n=3) and III : DHP under hepatic venous isolation using veno-venous bypass (n=5). Blood specimens were obtained to determine plasma drug levels until 60 min after ADR injection (3mg/kg body weight, 1 min). Blood fiow through DHP, which was averaged 200ml/min in both groups II and III, was monitored with ultrasonic flowmeter.
In groups I and II, peripheral ADR levels rapidly increased, reaching the peak values of 5.61±2.42 and 1.17±0.31μg/rnl respectively at 1 min after injection. The peak level in group III was markedly reduced,the value being 0.42±0.17μg/ml, which was 7.5% of the peak value of group I. The removal rates in groups II and III were 10.9 and 27.5% respectively.
In conclusion, DHP under hepatic venous isolation can be an useful method to reduce systemic distribution of ADR during hepatic artery infusion.


<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.